logo

Brainstorm Cell Therapeutics Inc. (BCLI)



Trade BCLI now with
  Date
  Headline
4/26/2021 7:19:58 AM BrainStorm Q1 Loss Per Share $0.19 Vs $0.32 Last Year
3/24/2021 7:12:49 AM BrainStorm Reports Positive Data In Phase 2 Study Evaluating NurOwn As Treatment For Progressive MS; Stock Surges
2/9/2021 9:03:05 AM BrainStorm Says Pleased With FDA Type C Meeting Outcome And Guidance On Requirements For Future Semi-automated Process
12/18/2020 7:20:34 AM BrainStorm Says All Dosing Completed In Ongoing Phase 2 Trial Evaluating NurOwn As A Treatment For Progressive MS
12/14/2020 7:18:14 AM BrainStorm Announces Initiation Of NurOwn Expanded Access Program
11/17/2020 7:32:29 AM BrainStorm Says Topline Results From NurOwn Phase 3 ALS Study did Not Meet Statistical Significance Results
10/26/2020 6:12:32 AM BrainStorm Selects RR&D As Partner To Expedite Site Selection And Design Services In The U.S.
10/15/2020 7:16:40 AM BrainStorm Cell Therapeutics Q3 Loss Per Share $0.14 Vs Loss $0.25 Last Year
9/29/2020 6:01:45 AM BrainStorm Appoints William White As SVP, Head Of Market Access & Pricing
9/16/2020 7:35:13 AM Brainstorm Announces Grant Of New Japanese Patent For NurOwn
9/2/2020 8:33:12 AM BrainStorm Appoints Anthony Waclawski As EVP, Global Head Of Regulatory Affairs
8/19/2020 8:22:46 AM BrainStorm Publishes New Data Supporting Proposed NurOwn Mechanism In ALS, Progressive MS And Alzheimer's Disease